Immunization against influenza A virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system

被引:79
作者
Brett, IC [1 ]
Johansson, BE [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Div Pediat Crit Care Med, Dept Pediat, New York, NY 10021 USA
关键词
influenza virus; vaccine;
D O I
10.1016/j.virol.2005.06.006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To simulate the 2003-2004 influenza season and compare available vaccination methods, immunologically naive mice were immunized with: influenza A virus hemagglutinin (rHA) and neuraminidase (rNA) from A/Panama/2007/99 H3N2 or A/Fujian/411/2002 H3N2 expressed by recombinant baculovirus, chromatographically purified, either as single antigens (rHA or rNA) or in combination (rHArNA); conventional inactivated monovalent (CIV) vaccines from each heterotypic strain; or a live-attenuated influenza (LAV) vaccine derived from the A/Panama/2007/99 strain. HA containing vaccines were highly immunogenic for the HA antigen, with no statistically significant differences among groups in the amount of homotypic anti-HA antibody induced. Little cross-reactive anti-HA antibody was induced by any vaccine, including LAV. Statistically, the greatest amount of anti-NA antibody was induced by the purified NA alone or in combination with purified HA; the least amount of anti-NA antibody was found in mice immunized with LAV or CIV Immunization with vaccines immunogenic for both HA and NA resulted in an immune response to both surface glycoproteins that suppressed homotypic, closely related heterotypic infection and had a greater reduction in mPVT following an infectious challenge by a distantly related heterotypic strain. These studies suggest that vaccines immunogenic for both HA and NA offer an increased level of protection from influenza. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 45 条
[1]  
ARCHETTI J, 1950, J EXP MED, V92, P1521
[2]   INFLUENZA VACCINATION OF ELDERLY PERSONS - REDUCTION IN PNEUMONIA AND INFLUENZA HOSPITALIZATIONS AND DEATHS [J].
BARKER, WH ;
MULLOOLY, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 244 (22) :2547-2549
[4]   Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine [J].
Belshe, RB ;
Gruber, WC ;
Mendelman, PM ;
Cho, I ;
Reisinger, K ;
Block, SL ;
Wittes, J ;
Iacuzio, D ;
Piedra, P ;
Treanor, J ;
King, J ;
Kotloff, K ;
Bernstein, DI ;
Hayden, FG ;
Zangwill, K ;
Yan, LH ;
Wolff, M .
JOURNAL OF PEDIATRICS, 2000, 136 (02) :168-175
[5]   Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003 [J].
Besselaar, TG ;
Botha, L ;
McAnerney, JM ;
Schoub, BD .
JOURNAL OF MEDICAL VIROLOGY, 2004, 73 (01) :71-78
[6]  
*CDC, 2004, MMWR-MORBID MORTAL W, V53, P284
[7]  
*CDC, 2003, MMWR-MORBID MORTAL W, V52, P1197
[8]   Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs [J].
Chen, Z ;
Matsuo, K ;
Asanuma, H ;
Takahashi, H ;
Iwasaki, T ;
Suzuki, Y ;
Aizawa, C ;
Kurata, T ;
Tamura, S .
VACCINE, 1999, 17 (7-8) :653-659
[9]   CORRELATED STUDIES OF A RECOMBINANT INFLUENZA-VIRUS VACCINE .3. PROTECTION AGAINST EXPERIMENTAL INFLUENZA IN MAN [J].
COUCH, RB ;
DOUGLAS, RG ;
FEDSON, DS ;
KASEL, JA .
JOURNAL OF INFECTIOUS DISEASES, 1971, 124 (05) :473-&
[10]   ADVANCES IN INFLUENZA-VIRUS VACCINE RESEARCH [J].
COUCH, RB .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1993, 685 :803-812